CTPI-2 is an inhibitor of the mitochondrial citrate carrier SLC25A1 (Kd = 3.5 μM) and a unique regulator of glycolysis that limits the metabolic plasticity of cancer stem cells (CSCs); it inhibits tumor growth in in vivo models of non-small cell lung cancer (NSCLC); prevents steatohepatitis and normalizes glucose tolerance; reduces circulating IL-6 levels while increasing anti-inflammatory cytokines IL-4 and IL-10; decreases monocyte chemoattractant protein-1 (MCP-1) and monokine induced by interferon-γ (MIG), thereby reducing neutrophil and monocyte infiltration; modulates citrate pools, lipogenic pathways, and gluconeogenesis; and effectively prevents weight gain or induces significant weight loss in high-fat diet (HFD)-fed C57BL/6J mice when administered intraperitoneally at 50 mg/kg every other day for 12 weeks.